Rahul S Loungani1, Marat Fudim2, Dave Ranney3, Ajar Kochar4, Marc D Samsky2, Desiree Bonadonna3, Akinobu Itoh5, Hiroo Takayama6, Koji Takeda6, Daniel Wojdyla2, Adam D DeVore2, Mani Daneshmand7. 1. Duke Clinical Research Institute and Division of Cardiology, Duke University School of Medicine, Durham, North Carolina. Electronic address: Rahul.loungani@duke.edu. 2. Duke Clinical Research Institute and Division of Cardiology, Duke University School of Medicine, Durham, North Carolina. 3. Department of Surgery, Duke University School of Medicine, Durham, North Carolina. 4. Division of Cardiology, Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, Massachusetts. 5. Department of Surgery, Washington University School of Medicine, St Louis, Missouri. 6. Department of Surgery, Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, New York. 7. Department of Surgery, Division of Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, Georgia.
Abstract
BACKGROUND: Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly used as a life-saving therapy for patients with cardiovascular collapse, but identifying patients unlikely to benefit remains a challenge. METHODS AND RESULTS: We created the RESCUE registry, a retrospective, observational registry of adult patients treated with VA-ECMO between January 2007 and June 2017 at 3 high-volume centers (Columbia University, Duke University, and Washington University) to describe short-term patient outcomes. In 723 patients treated with VA-ECMO, the most common indications for deployment were postcardiotomy shock (31%), cardiomyopathy (including acute heart failure) (26%), and myocardial infarction (17%). Patients frequently suffered in-hospital complications, including acute renal dysfunction (45%), major bleeding (41%), and infection (33%). Only 40% of patients (n = 290) survived to discharge, with a minority receiving durable cardiac support (left ventricular assist device [n = 48] or heart transplantation [n = 7]). Multivariable regression analysis identified risk factors for mortality on ECMO as older age (odds ratio [OR], 1.26; 95% confidence interval [CI], 1.12-1.42) and female sex (OR, 1.44; 95% CI, 1.02-2.02) and risk factors for mortality after decannulation as higher body mass index (OR 1.17; 95% CI, 1.01-1.35) and major bleeding while on ECMO support (OR, 1.92; 95% CI, 1.23-2.99). CONCLUSIONS: Despite contemporary care at high-volume centers, patients treated with VA-ECMO continue to have significant in-hospital morbidity and mortality. The optimization of outcomes will require refinements in patient selection and improvement of care delivery.
BACKGROUND: Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly used as a life-saving therapy for patients with cardiovascular collapse, but identifying patients unlikely to benefit remains a challenge. METHODS AND RESULTS: We created the RESCUE registry, a retrospective, observational registry of adult patients treated with VA-ECMO between January 2007 and June 2017 at 3 high-volume centers (Columbia University, Duke University, and Washington University) to describe short-term patient outcomes. In 723 patients treated with VA-ECMO, the most common indications for deployment were postcardiotomy shock (31%), cardiomyopathy (including acute heart failure) (26%), and myocardial infarction (17%). Patients frequently suffered in-hospital complications, including acute renal dysfunction (45%), major bleeding (41%), and infection (33%). Only 40% of patients (n = 290) survived to discharge, with a minority receiving durable cardiac support (left ventricular assist device [n = 48] or heart transplantation [n = 7]). Multivariable regression analysis identified risk factors for mortality on ECMO as older age (odds ratio [OR], 1.26; 95% confidence interval [CI], 1.12-1.42) and female sex (OR, 1.44; 95% CI, 1.02-2.02) and risk factors for mortality after decannulation as higher body mass index (OR 1.17; 95% CI, 1.01-1.35) and major bleeding while on ECMO support (OR, 1.92; 95% CI, 1.23-2.99). CONCLUSIONS: Despite contemporary care at high-volume centers, patients treated with VA-ECMO continue to have significant in-hospital morbidity and mortality. The optimization of outcomes will require refinements in patient selection and improvement of care delivery.
Authors: David D Berg; Christopher F Barnett; Benjamin B Kenigsberg; Alexander Papolos; Carlos L Alviar; Vivian M Baird-Zars; Gregory W Barsness; Erin A Bohula; Joseph Brennan; James A Burke; Anthony P Carnicelli; Sunit-Preet Chaudhry; Paul C Cremer; Lori B Daniels; Andrew P DeFilippis; Daniel A Gerber; Christopher B Granger; Steven Hollenberg; James M Horowitz; James D Gladden; Jason N Katz; Ellen C Keeley; Norma Keller; Michael C Kontos; Patrick R Lawler; Venu Menon; Thomas S Metkus; P Elliott Miller; Jose Nativi-Nicolau; L Kristin Newby; Jeong-Gun Park; Nicholas Phreaner; Robert O Roswell; Steven P Schulman; Shashank S Sinha; R Jeffrey Snell; Michael A Solomon; Jeffrey J Teuteberg; Wayne Tymchak; Sean van Diepen; David A Morrow Journal: Circ Heart Fail Date: 2019-11-11 Impact factor: 8.790
Authors: Aidan J C Burrell; Vincent A Pellegrino; Rory Wolfe; Wen Kai Wong; David Jamie Cooper; David M Kaye; David V Pilcher Journal: J Crit Care Date: 2015-06-03 Impact factor: 3.425
Authors: Alexander Sacha C Richardson; Matthieu Schmidt; Michael Bailey; Vincent A Pellegrino; Peter T Rycus; David V Pilcher Journal: Resuscitation Date: 2016-12-16 Impact factor: 5.262